Share this article
Share this article
KRAKOW, Poland, June 1, 2021 /PRNewswire/ Ryvu Therapeutics (WSE: RVU) today announced that the latest results from the DIAMOND-01 clinical trial (CLI24-001; clinicaltrials.gov identifier NCT03008187) will be disclosed through poster presentations at both the upcoming American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) Virtual Congresses, to be held on June 4-8, and June 9-17, respectively.
DIAMOND-01 is a First-in-Human, Phase I/II, dose escalation and cohort expansion trial of SEL24 (MEN1703), a first in class, orally available, dual PIM/FLT3 inhibitor in-licensed by Menarini Group from Ryvu Therapeutics, which is currently investigated as single agent for the treatment of patients with Acute Myeloid Leukemia (AML).
Results Confirmed Manageable Safety Profile of SEL24/MEN1703 and Showed Preliminary Efficacy in Relapsed/Refractory Acute Myeloid Leukemia Data to be Presented at ASCO and EHA Virtual